{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T22:44:40Z","timestamp":1759099480385},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,12,21]],"date-time":"2006-12-21T00:00:00Z","timestamp":1166659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1007\/s10198-006-0006-5","type":"journal-article","created":{"date-parts":[[2006,12,20]],"date-time":"2006-12-20T15:52:59Z","timestamp":1166629979000},"page":"51-57","source":"Crossref","is-referenced-by-count":13,"title":["Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany"],"prefix":"10.1007","volume":"8","author":[{"given":"B.","family":"Br\u00fcggenj\u00fcrgen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Ehlken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-J.","family":"Rupprecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. N.","family":"Willich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,12,21]]},"reference":[{"key":"6_CR1","unstructured":"Statistisches Bundesamt. Datenreport 2004 - Zahlen und Fakten f\u00fcr die Bundesrepublik Deutschland. Schriftenreihe Band 440. Bonn 2004"},{"key":"6_CR2","unstructured":"Statistisches Bundesamt. http:\/\/www.destatis.de . (November 2004)"},{"key":"6_CR3","unstructured":"Gesundheitsberichtserstattung des Bundes 2004 [Federal Health Report]. http:\/\/www.gbe-bund.de (September 2004)"},{"key":"6_CR4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s003920050285","volume":"88","author":"H Klepzig","year":"1999","unstructured":"Klepzig, H., Krobot, K., Flettner, R., Winten, G., Zeiher, A.M.: Determinanten der Behandlungskosten der instabilen Angina pectoris. Z. Kardiol. 88, 261\u2013269 (1999)","journal-title":"Z Kardiol"},{"issue":"12","key":"6_CR5","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s003920050381","volume":"88","author":"G Klever-Deichert","year":"1999","unstructured":"Klever-Deichert, G., Hinzpeter, B., Hunsche, E., Lauterbach, K.W.: Costs of coronary heart diseases over the remaining life time in coronary heart disease cases--an analysis of the current status of coronary heart disease cases in Germany from the social perspective. Z. Kardiol. 88(12), 991\u20131000 (1999)","journal-title":"Z Kardiol"},{"key":"6_CR6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000067119","volume":"15","author":"C Weimar","year":"2003","unstructured":"Weimar, C., Weber, C., Wagner, M., Busse, O., Haberl, R.L., Lauterbach, K.W., Diener, H.C.: On behalf of the German Stroke Data Bank Collaborators. Management pattern and health care use after intracerebral hemorrhage. A cost-of-illness study from a societal perspective in Germany. Cerebrovasc. Dis. 15, 29\u201336 (2003)","journal-title":"Cerebrovasc Dis"},{"issue":"4","key":"6_CR7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s10389-005-0112-3","volume":"13","author":"B Br\u00fcggenj\u00fcrgen","year":"2005","unstructured":"Br\u00fcggenj\u00fcrgen, B., Rupprecht, H.J., Willich, S.N., Spannagl, M., Ehlken, B., Smala, A., Berger, K., Diener, H.C.: Cost of atherothrombotic diseases\u2014myocardial infarction (MI), ischaemic stroke (IS) and peripheral arterial occlusive disease (PAD)\u2014in Germany. J. Public Health 13(4), 216\u2013224 (2005)","journal-title":"J Public Health"},{"issue":"7","key":"6_CR8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial Investigators","year":"2001","unstructured":"The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N. Engl. J. Med. 345(7):494\u2013502 (2001)","journal-title":"N Engl J Med"},{"issue":"5","key":"6_CR9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1365-2796.2004.01324.x","volume":"255","author":"P Lindgren","year":"2004","unstructured":"Lindgren, P., Jonsson, B., Yusuf, S.: Cost-effectiveness of clopidogrel in acute coronary syndrome in Sweden: a long-term model based on the CURE trial. J. Intern. Med. 255(5), 562\u2013570 (2004)","journal-title":"J Intern Med"},{"issue":"1","key":"6_CR10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF03321553","volume":"1","author":"B Br\u00fcggenj\u00fcrgen","year":"2003","unstructured":"Br\u00fcggenj\u00fcrgen, B., Ehlken, B., Willich, S.: Kosteneffektivit\u00e4t von Clopidogrel bei zus\u00e4tzlicher Gabe zu Acetylsalicyls\u00e4ure (ASS) vs. ASS Monotherapie in Deutschland auf der Basis der CURE-Studie. Pharmacoecon. German Res. Articles 1(1), 15\u201324 (2003)","journal-title":"Pharmacoecon German Res Articles"},{"issue":"4","key":"6_CR11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","volume":"13","author":"FA Sonnenberg","year":"1993","unstructured":"Sonnenberg, F.A., Beck, R.: Markov models in medical decision making: a practical guide. Med. Dec. Making. 13(4), 322\u2013338 (1993)","journal-title":"Med Dec Making"},{"issue":"40","key":"6_CR12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1055\/s-2000-7700","volume":"125","author":"F Fischer","year":"2000","unstructured":"Fischer, F., Schiele, R., Zahn, R., Schneider, S., Wagner, S., Senges, J.: Comparison of acute myocardial infarct in the old and new lands of unified Germany, 1996\u20131998. Data of the myocardial infarct register (MIR). Dtsch. Med. Wochenschr. 125(40), 1181\u20131185 (2000)","journal-title":"Dtsch Med Wochenschr"},{"key":"6_CR13","unstructured":"Berliner Herzinfarktregister. Ergebnisse des BHIR 1999\u20132001 [Myocardial Infarct Register Berlin]. http:\/\/www.herzinfarktregister.de\/fakten (June 2004)"},{"issue":"7","key":"6_CR14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-2004-818624","volume":"129","author":"PU Heuschmann","year":"2004","unstructured":"Heuschmann, P.U., Kolominsky-Rabas, P.L., Misselwitz, B., Hermanek, P., Leffmann, C., Von Reutern, G.M., Lachenmeyer, L., Bucker-Nott, H.J., Berger, K.: Factors influencing duration of hospitalization after stroke in Germany. Dtsch. Med. Wochenschr. 129(7), 299\u2013304 (2004)","journal-title":"Dtsch Med Wochenschr"},{"key":"6_CR15","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/hs1101.098524","volume":"32","author":"A Grau","year":"2001","unstructured":"Grau, A., Weimar, C., Buggle Heinrich, A., Goertler, M., Neumaier, S., Glahn, J., Brandt, T., Hacke, W., Diener, C.: Risk factors, outcome and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 32, 2559\u20132566 (2001)","journal-title":"Stroke"},{"key":"6_CR16","unstructured":"Rote Liste: Arzneimittelverzeichnis f\u00fcr Deutschland. Tariff list for drugs in Germany. Editio Cantor Verlag, Aulendorf (2005)"},{"key":"6_CR17","first-page":"A62","volume":"4","author":"Hannoveraner Konsens Gruppe","year":"1999","unstructured":"Hannoveraner Konsens Gruppe: Dt. Empfehlungen zur gesundheits\u00f6konomischen Evaluation\u2013Revidierte Fassung des Hannoveraner Konsens. Gesundheits\u00f6kon. Qualit\u00e4tsmanage. 4:A62\u2013A65 (1999)","journal-title":"Gesundheits\u00f6kon Qualit\u00e4tsmanage"},{"issue":"6","key":"6_CR18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1098-3015(10)61595-1","volume":"6","author":"P Lindgren","year":"2003","unstructured":"Lindgren, P., Jonsson, B., Spiesser, J., Carita, P., Gabriel, S.: Short and long term cost effectiveness analysis of clopidogrel in patients with acute coronary syndrome without ST-segment elevation (ACS) in Scandinavian countries. (Podium presentation at ISPOR 2003 in Barcelona). Value in Health. 6(6), 621 (2003)","journal-title":"Value in Health"},{"key":"6_CR19","first-page":"174","volume":"7","author":"A Frei","year":"2004","unstructured":"Frei, A., Lindgren, P., Meiner, B.: Cost-effectiveness of clopidogrel in patients with acute coronary syndrome in Switzerland. Kardiovaskul\u00e4re Medizin. 7, 174\u2013180 (2004)","journal-title":"Kardiovaskul\u00e4re Medizin"},{"issue":"1","key":"6_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF03321557","volume":"2","author":"B Schwarz","year":"2004","unstructured":"Schwarz, B., Lindgren, P., Nanz, S.: Die Langzeit-Kosteneffektivit\u00e4t von Clopidogrel zus\u00e4tzlich zu Azetylsalizyls\u00e4ure bei Patienten mit akutem Koronarsyndrom ohne ST-Streckenhebung im \u00f6sterreichischen Gesundheitssystem. Pharmacoeconomics\u2013German Research Articles 2(1), 31\u201341 (2004)","journal-title":"Pharmacoeconomics\u2013German Research Articles"},{"issue":"6","key":"6_CR21","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jacc.2004.11.051","volume":"45","author":"WS Weintraub","year":"2005","unstructured":"Weintraub, W.S., Mahoney, E.M., Lamy, A., Culler, S., Yuan, Y., Caro, J., Gabriel, S., Yusuf, S.: On behalf of the CURE study investigators. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. JACC. 45(6), 838\u2013845 (2005)","journal-title":"JACC."},{"key":"6_CR22","first-page":"178","volume":"17","author":"S Silber","year":"2004","unstructured":"Silber, S., Mahn, M.: Sekund\u00e4rprophylaxe mit Clopidogrel bei Patienten mit klinisch manifester Atherothrombose in der t\u00e4glichen haus\u00e4rztlichen Praxis. Perfusion. 17, 178\u2013184 (2004)","journal-title":"Perfusion"},{"issue":"4","key":"6_CR23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7326\/0003-4819-142-4-200502150-00007","volume":"142","author":"MD Schleinitz","year":"2005","unstructured":"Schleinitz, M.D., Heidenreich, P.A.: A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann. Intern. Med. 142(4):251\u2013259 (2005)","journal-title":"Ann Intern Med"},{"issue":"5","key":"6_CR24","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","volume":"7","author":"HG Eichler","year":"2004","unstructured":"Eichler, H.G., Kong, S.X., Gerth, W.C., Mavros, P., J\u00f6nsson, B.: Use of cost-effectiveness analysis in health care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value in Health 7(5), 518\u2013528 (2004)","journal-title":"Value in Health"},{"key":"6_CR25","unstructured":"Towse, A., Pritchard, C.: Does NICE have a threshold? An external view. In: Towse, A., Pritchard, C., Devlin, N. (eds.) Cost-effectiveness Thresholds. Economic and Ethical Issues. King\u2019s Fund and Office of Health Economics, London (2002)"},{"key":"6_CR26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1539-6924.1995.tb00330.x","volume":"15","author":"T Tengs","year":"1995","unstructured":"Tengs, T., Adams, M., Pliskin, J., et al.: Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 15:369\u2013390 (1995)","journal-title":"Risk Anal"},{"issue":"1","key":"6_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-6296(96)00506-1","volume":"16","author":"AM Garber","year":"1997","unstructured":"Garber, A.M., Phelps, C.E.: Economic foundations of cost-effectiveness analysis. J. Health Econ. 16(1), 1\u201331 (1997)","journal-title":"J Health Econ"},{"issue":"5","key":"6_CR28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/hec.853","volume":"13","author":"RH Chapman","year":"2004","unstructured":"Chapman, R.H., Berger, M., Weinstein, M.C., Weeks, J.C., Goldie, S., Neumann, P.J.: When does quality-adjusting life-years matter in cost-effectiveness analysis? Health Econ. 13(5):429\u2013436 (2004)","journal-title":"Health Econ"},{"issue":"2","key":"6_CR29","first-page":"183","volume":"15","author":"B Robberstad","year":"2005","unstructured":"Robberstad, B.: QALYs vs. DALYs vs LYs gained: What are the differences, and what difference do they make for health care priority setting? Norsk Epidemiol. 15(2), 183\u2013191 (2005)","journal-title":"Norsk Epidemiol"},{"issue":"Supp C","key":"6_CR30","first-page":"C59","volume":"19","author":"CJ Troche","year":"1998","unstructured":"Troche, C.J., Tacke, J., Hinzpeter, B., Danner, M., Lauterbach, K.W: Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur. Heart J. 19(Supp C), C59\u2013C65 (1998)","journal-title":"Eur Heart J"},{"key":"6_CR31","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2165\/00019053-200422150-00001","volume":"22","author":"PH Sch\u00e4dlich","year":"2004","unstructured":"Sch\u00e4dlich, P.H., Brecht, J.G., Rangoonwala, B., Huppertz, E.: Cost effectiveness of Ramipril in patients at high risk for cardiovascular events\u2013Economic evaluation of the heart outcomes prevention evaluation (HOPE) study for Germany from the perspective of statutory health insurance. Pharmacoeconomics 22, 955\u2013973 (2004)","journal-title":"Pharmacoeconomics"},{"key":"6_CR32","unstructured":"WHO Commission on Macroeconomics and Health: Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. World Health Organization, Geneva (2001)"},{"issue":"3","key":"6_CR33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O","volume":"9","author":"CJ Murray","year":"2000","unstructured":"Murray, C.J., Evans, D.B., Acharya, A., Baltussen, R.M.: Development of WHO guidelines on generalised cost-effectiveness analysis. Health Econ. 9(3), 235\u2013251 (2000)","journal-title":"Health Econ"},{"key":"6_CR34","unstructured":"OECD. http:\/\/www.oecd. org (February 2005)"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-006-0006-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-006-0006-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-006-0006-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T11:02:45Z","timestamp":1559127765000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-006-0006-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,21]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["6"],"URL":"https:\/\/doi.org\/10.1007\/s10198-006-0006-5","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,21]]}}}